{"id":"atg-ptcy","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Hemorrhagic cystitis"}]},"_chembl":{"chemblId":"CHEMBL4482864","moleculeType":"Small molecule","molecularWeight":"494.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Antithymocyte globulin (ATG) is a polyclonal antibody that depletes T lymphocytes, reducing the risk of graft rejection and GVHD. Post-transplant cyclophosphamide (PTCy) is a high-dose chemotherapy agent administered after transplantation that selectively eliminates alloreactive T cells while sparing hematopoietic stem cells and regulatory T cells, further preventing GVHD while maintaining graft-versus-leukemia effects.","oneSentence":"ATG/PTCy is a combination immunosuppressive regimen that depletes T cells and provides graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:24.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation"},{"name":"Hematologic malignancies undergoing allogeneic transplantation"}]},"trialDetails":[{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06705062","phase":"PHASE3","title":"Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease","enrollment":316},{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT05457556","phase":"PHASE3","title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-03-15","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":435},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT06984536","phase":"PHASE2","title":"Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome, Acute Leukemia","enrollment":40},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT06108739","phase":"PHASE3","title":"ATG Plus Low-dose PT-Cy for GVHD Prevention","status":"TERMINATED","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"Hematologic Malignancy","enrollment":66},{"nctId":"NCT04202835","phase":"PHASE2","title":"ATG Plus PTCy vs ATG for CGVHD Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"McMaster University","startDate":"2020-10-14","conditions":"Acute Leukemia, Myelodysplasia, Chronic Graft-versus-host-disease","enrollment":80},{"nctId":"NCT02162420","phase":"NA","title":"Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2015-01-10","conditions":"Dyskeratosis Congenita, Aplastic Anemia","enrollment":61},{"nctId":"NCT06299462","phase":"PHASE1, PHASE2","title":"PTCy and ATG for MSD and MUD Transplants","status":"RECRUITING","sponsor":"Instituto Nacional de Cancer, Brazil","startDate":"2024-06-14","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT06686173","phase":"","title":"Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-02-01","conditions":"High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML","enrollment":114},{"nctId":"NCT05153226","phase":"PHASE3","title":"GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG","status":"ACTIVE_NOT_RECRUITING","sponsor":"DKMS gemeinnützige GmbH","startDate":"2022-03-02","conditions":"Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML","enrollment":640},{"nctId":"NCT06041893","phase":"","title":"Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2023-05-29","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":20},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT06378060","phase":"PHASE2","title":"Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Hematology department of the 920th hospital","startDate":"2024-03-01","conditions":"Severe Aplastic Anemia","enrollment":30},{"nctId":"NCT06238245","phase":"PHASE2","title":"Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-02-28","conditions":"Graft-versus-host Disease, Hematological Malignancies","enrollment":22},{"nctId":"NCT03357159","phase":"PHASE2","title":"Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2018-09-06","conditions":"Graft Versus Host Disease","enrollment":30},{"nctId":"NCT06075212","phase":"","title":"Immune Reconstitution After Allo-HSCT and Blinatumomab","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2023-10-01","conditions":"Leukemia, Lymphoid","enrollment":20},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT04888741","phase":"PHASE2","title":"Methods of T Cell Depletion Trial (MoTD)","status":"UNKNOWN","sponsor":"University of Birmingham","startDate":"2021-02-22","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia","enrollment":400},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT06000982","phase":"PHASE3","title":"Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-01","conditions":"GVHD","enrollment":138},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT03263767","phase":"PHASE2","title":"Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2018-01-15","conditions":"Graft Versus Host Disease","enrollment":47},{"nctId":"NCT03689465","phase":"PHASE4","title":"PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-10-29","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT03395860","phase":"PHASE2","title":"Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2017-05-30","conditions":"Graft-versus-host-disease, Prophylaxis","enrollment":100},{"nctId":"NCT02702960","phase":"PHASE2","title":"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03","conditions":"Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ATG/PTCy","genericName":"ATG/PTCy","companyName":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","companyId":"shanghai-general-hospital-shanghai-jiao-tong-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATG/PTCy is a combination immunosuppressive regimen that depletes T cells and provides graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation. Used for Graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation, Hematologic malignancies undergoing allogeneic transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}